0.768
-0.02 (-2.12%)
| Penutupan Terdahulu | 0.784 |
| Buka | 0.772 |
| Jumlah Dagangan | 270,420 |
| Purata Dagangan (3B) | 424,032 |
| Modal Pasaran | 73,873,472 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.27 |
| Harga / Jualan (P/S) | 0.500 |
| Harga / Buku (P/B) | 0.650 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Keuntungan | -25.72% |
| Margin Operasi (TTM) | -48.87% |
| EPS Cair (TTM) | -0.320 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -18.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 37.12% |
| Nisbah Semasa (MRQ) | 1.66 |
| Aliran Tunai Operasi (OCF TTM) | 6.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 16.48 M |
| Pulangan Atas Aset (ROA TTM) | -6.60% |
| Pulangan Atas Ekuiti (ROE TTM) | -25.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Assertio Holdings, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.75 |
|
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.52% |
| % Dimiliki oleh Institusi | 26.92% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2025 | Pengumuman | Assertio Reports Third Quarter 2025 Financial Results |
| 28 Oct 2025 | Pengumuman | Assertio Announces Leadership Transition |
| 15 Sep 2025 | Pengumuman | Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV |
| 10 Sep 2025 | Pengumuman | Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |